Tag: Vein

Neurosurgery 98:588–596, 2026

This study reports outcomes from a 23-year, prospectively maintained cohort of 523 patients with unilateral Type 1 trigeminal neuralgia treated by microvascular decompression using vein sacrifice and a Teflon transposition technique. Primary outcome was long-term pain-free survival without medications, with median follow-up 8.2 years and 5-, 10-, 15-year pain-free rates of 77.6%, 72.5%, and 69.7%, respectively.

Operative details, complications, and reoperation rates are presented: arterial transposition was performed when possible, veins contacting the nerve were sacrificed, and Teflon pledgets used to maintain separation. Complications were uncommon and generally non-disabling (most frequent: facial numbness, diplopia); true Teflon granulomas were rare but noted in isolated reoperations.

Microvascular decompression (MVD) is the most effective surgical treatment for medically unresponsive Type 1 trigeminal neuralgia (TN), aiming to eliminate neurovascular contact with the trigeminal nerve using arterial transposition, vein sacrifice, and polytetrafluoroethylene (PTFE, “Teflon”) implantation when appropriate.

Study outcomes show that 92.7% of patients were initially pain-free without medications after MVD, with pain-free survival rates of 77.6% at 5 years, 72.5% at 10 years, and 69.7% at 15 years.

Operative technique selection depends on intraoperative findings: arteries are transposed and secured with PTFE whenever possible, veins in contact with the nerve are sacrificed, and partial sensory rhizotomy is reserved for cases without significant vascular compression.

Complication rates are low; the most common was new or worsened facial numbness (7.1%), with higher rates when veins were sacrificed (6.9%) versus arterial decompression alone (1.6%). Venous infarction occurred in 0.6% of patients, and Teflon granuloma in 0.4%.

Pain-free survival was lower in women (hazard ratio 1.48, P = .03), but not associated with pain duration, previous ablative surgery, or new facial numbness.

Vein sacrifice is generally safe and facilitates surgical exposure, though it carries a low but real risk of venous complications; evidence is mixed regarding whether preserving or sacrificing the superior petrosal vein impacts complication rates.

PTFE (“Teflon”) material is widely used for vessel transposition; however, true Teflon granulomas—characterized by mass effect, edema, and inflammatory response—are rare and should not be used to describe all cases of recurrent pain with adherent PTFE.

Terminology precision is important: “Teflon” is a trademark for Chemours’ PTFE products, and not all PTFE felt used in surgery is identical. Variability in material properties may affect surgical outcomes and study reproducibility.